Welcome to our dedicated page for Insmed news (Ticker: INSM), a resource for investors and traders seeking the latest updates and insights on Insmed stock.
Insmed Inc (NASDAQ: INSM) is a global biopharmaceutical leader developing innovative therapies for rare pulmonary diseases and chronic inflammatory conditions. This news hub provides investors and healthcare professionals with essential updates on clinical trials, regulatory milestones, and therapeutic advancements.
Access real-time information about Insmed's FDA submissions, partnership announcements, and research breakthroughs. Our curated collection includes updates on ARIKAYCE commercialization, brensocatib clinical studies, and novel inhalation technologies like TPIP platform developments.
Key content categories include treatment approvals, scientific conference presentations, patent filings, and manufacturing expansions. All materials are sourced directly from company filings and verified industry publications to ensure accuracy.
Bookmark this page for streamlined access to Insmed's latest developments in targeted pulmonary therapy and rare disease research. Check regularly for critical updates affecting treatment accessibility and clinical progress.
Insmed (Nasdaq: INSM) announced on December 17, 2025 that the Phase 2b BiRCh study of brensocatib in chronic rhinosinusitis without nasal polyps (CRSsNP) did not meet its primary or secondary efficacy endpoints in either the 10 mg or 40 mg arms, and Insmed has discontinued the CRSsNP program effective immediately.
Topline placebo-adjusted least-squares means for 28-day average sTSS at Week 24 were placebo -2.44, brensocatib 10 mg -2.21, and brensocatib 40 mg -2.33. Safety was consistent with prior studies with no new signals. The company also acquired INS1148, a Phase 2–ready monoclonal antibody targeting SCF248, and plans initial development in interstitial lung disease and moderate-to-severe asthma.
Insmed (Nasdaq: INSM) will present seven abstracts at the European Respiratory Society (ERS) 2025 Congress, Sept 27–Oct 1, 2025, in Amsterdam.
Key highlights include data from a Phase 2b study of treprostinil palmitil inhalation powder (TPIP) in pulmonary arterial hypertension (PAH) featured in the Congress's late‑breaking ALERT session, and three prespecified subgroup analyses from the Phase 3 ASPEN trial evaluating brensocatib, including efficacy and safety data in Japanese patients with non‑cystic fibrosis bronchiectasis (NCFB).
Presentations span an oral Elicium session, ALERT clinical trials session, and multiple poster sessions with specified presenters and scheduled times during Sept 28–30, 2025.
Insmed (Nasdaq: INSM) granted inducement awards to 92 new employees under its 2025 Inducement Plan to meet Nasdaq Listing Rule 5635(c)(4).
On November 28, 2025 the company issued 44,273 restricted stock units and options to purchase an aggregate of 2,490 shares at an exercise price of $207.77 per share (the Nasdaq closing price on the grant date).
The restricted stock units vest over four years with 25% vesting each anniversary of the first day of the month after the grant. Options have a 10-year term and a four-year vesting schedule: 25% at the first anniversary and 12.5% every six months thereafter, subject to continued service.
Insmed (Nasdaq: INSM) announced that the European Commission approved BRINSUPRI (brensocatib) 25 mg on November 18, 2025, as the first and only treatment for non-cystic fibrosis bronchiectasis (NCFB) in the EU for patients 12+ with ≥2 exacerbations in the prior 12 months.
Approval was granted after EMA accelerated assessment and is supported by Phase 3 ASPEN and Phase 2 WILLOW data showing a 19.4% reduction in annual exacerbation rate and statistically smaller FEV1 decline at week 52. EU access efforts begin in early 2026; U.K. and Japan reviews are ongoing.
Insmed (Nasdaq: INSM) held its fourth annual Global Day of Good on November 13, 2025, mobilizing more than 1,200 employees across the U.S., Europe, and Japan for simultaneous volunteer activities.
Teams supported health, education, and human services through meal-packing, care packages for children with serious diseases, STEM and hygiene kits, book translation, and outdoor space restoration. The company offers year-round volunteer programs, matching gifts, and paid volunteer time.
Insmed (Nasdaq: INSM) announced management will present at two investor conferences in November and December 2025: the Jefferies Global Healthcare Conference in London on Tuesday, November 18, 2025 at 8:30 a.m. GT / 3:30 a.m. ET, and the Evercore 8th Annual Healthcare Conference in Coral Gables, Florida on Tuesday, December 2, 2025 at 11:15 a.m. ET.
Both presentations will be webcast live and archived for 30 days on Insmed's investor relations website at www.insmed.com.
Insmed (Nasdaq: INSM) reported third-quarter 2025 results and a business update on October 30, 2025. Total revenue was $142.3 million in Q3 2025, driven by ARIKAYCE $114.3M (+22% YoY) and BRINSUPRI $28.1M following FDA approval and U.S. launch. The company raised full-year ARIKAYCE guidance to $420M–$430M (15%–18% YoY growth).
R&D and SG&A each were $186.4M in Q3, and Insmed reported a net loss of $370.0M (−$1.75/share). Cash and marketable securities totaled about $1.7B as of Sept 30, 2025. Key clinical catalysts are expected through 2026 across ARIKAYCE, brensocatib, and TPIP programs.
Insmed (Nasdaq: INSM) ranked No. 1 on Science's 2025 Top Biopharma Employers list, marking a record fifth consecutive year at the top, announced Oct. 23, 2025. The ranking is based on about 5,500 survey responses, primarily from North America (66%), Europe (20%), and Asia/Pacific Rim (9%). The company linked the recognition to a people-first culture and cited recent clinical successes and regulatory milestones as drivers of growth. Insmed highlighted strengths in corporate image, financial prowess, leadership, work culture, and intellectual challenge. More details and rankings are available on the publisher's feature and Insmed's culture page.
Insmed (Nasdaq: INSM) announced that the EMA Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion on BRINSUPRI (brensocatib 25 mg) on October 17, 2025, recommending approval for treatment of non-cystic fibrosis bronchiectasis (NCFB) in patients aged 12 years and older with two or more exacerbations in the prior 12 months.
BRINSUPRI was reviewed under the CHMP's accelerated assessment and had prior PRIME designation; the opinion is based on Phase 3 ASPEN and Phase 2 WILLOW data published in the New England Journal of Medicine. The European Commission will issue a final decision in the coming months.
Insmed (Nasdaq: INSM) will present six abstracts from the Phase 3 ASPEN trial of BRINSUPRI (brensocatib) at CHEST 2025 in Chicago, Oct 19–22, 2025. Presentations include prespecified and post‑hoc subgroup analyses, a late‑breaking high‑resolution CT substudy on structural lung changes, NSP (neutrophil serine protease) suppression data, and analyses of efficacy, symptom burden, and biomarker effects in patients with non‑cystic fibrosis bronchiectasis (NCFB).
Sessions cover COPD comorbidity, Asian population outcomes, BEST symptom assessments during and outside exacerbations, and multiple poster and oral presentations led by named investigators across Oct 20–22, 2025.
FAQ
What is the current stock price of Insmed (INSM)?
What is the market cap of Insmed (INSM)?
